After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCI

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute (NCI) for the past 5 years, says that he will resign his post in April of this year. He will join IVAX Corporation (Miami), a manufacturer of generic drugs and IV drug delivery devices, where he plans to work on developing new drugs.

WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute(NCI) for the past 5 years, says that he will resign his postin April of this year. He will join IVAX Corporation (Miami),a manufacturer of generic drugs and IV drug delivery devices,where he plans to work on developing new drugs.

Dr. Broder first joined the NCI in 1972 as a researcher. He wasthe leader of a group that discovered the therapeutic benefitsof the antiretroviral agent zidovudine (Retrovir, AZT) in 1985.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content